Advanced seminoma—Treatment results and prognostic factors for survival after first‐line, cisplatin‐based chemotherapy and for patients with recurrent disease
Dany Gholam(Institut Gustave Roussy), Christine Théodore(Hôpital Foch)
Cited by 64
Related Papers
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
|Journal of Clinical Oncology|2001|628